Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis

Tumor necrosis factor (TNF) inhibitors improved clinical outcomes for patients with psoriasis but are limited by their high cost. There are several biosimilar options approved for the treatment of psoriasis which provides a lower-cost alternative and the potential to increase treatment availability...

Full description

Bibliographic Details

Published in:	Journal of Dermatological Treatment
Main Authors:	Rachel C. Ruda, Katherine A. Kelly, Steven R. Feldman
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	psoriasis tnf-inhibitor biosimilar biological agents
Online Access:	http://dx.doi.org/10.1080/09546634.2022.2140569